Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non–small cell lung cancer patients with <scp>K</scp>RAS‐activated tumors

Abstract

Reolysin in combination with paclitaxel and carboplatin was well tolerated. The observed response rate suggests a benefit of the reovirus for chemotherapy. A follow-up randomized study is recommended. The proportion of patients surviving longer than 2 years (30%) suggests a second/third-line treatment effect or possibly the triggering of an immune response after tumor reovirus infiltration.